Please assess the completion status of the following clinical trial:

Trial Title: A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is in good health as determined by the Investigator based on medical history, physical examination, and routine laboratory tests at a screening evaluation.~* Male or female, aged between 18 and 55 years inclusive~* Body weight ≥ 50 kg and Body Mass Index (BMI) ≥ 18 kg/m2 and ≤ 30kg/m2~* Subject must provide written informed consent~* Serosuitable to the challenge virus.~Exclusion Criteria:~* History or evidence of any clinically significant or currently active major clinical illness.~* Any significant abnormality altering the anatomy of the nose or nasopharynx~* Any nasal or sinus surgery within six months of the study~* Abnormal lung function~* Positive human immunodeficiency virus (HIV), active hepatitis A (HAV), B (HBV), or C (HCV) test.~* Presence of cold like symptoms and/or fever on admission for the study~* History or currently active symptoms suggestive of upper or lower respiratory tract infection within 6 weeks of the study~* History of anaphylaxis-and/or a history of severe allergic reaction or significant intolerance to any food or drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- PC786 (Type: EXPERIMENTAL): Repeat dose
- Placebo/vehicle (Type: PLACEBO_COMPARATOR): Repeat dose

Based on this trial design, predict the completion outcome and termination type (if applicable).